D&MD s Drug Targets from Genomics: Evolving Tools for Discovery seeks to examine the roles omic technologies play in pharma R&D, to asses their value to pharma, and to predict their future role and value.
This Report analyzes current and projected revenues from sales of omic technology-based products (reagents and consumables), which in 2004 totaled nearly $1.5 billion. Revenues are projected to increase to $2.3 billion by 2009. Also provided is a breakdown of revenues into transcriptomic, proteomic, metabolomic, and genotyping categories.
TABLE OF CONTENTS
CHAPTER 1: EXECUTIVE SUMMARY
- Omics and Pharma: The Context
- Omics in Pharma R&D Today
- Market Implications of R&D Trends
CHAPTER 2: INTRODUCTION
- Scope and Nature of this Report
CHAPTER 3: EVOLUTION OF DRUG DISCOVERY
- Drug Discovery Pre-Industrialization
- The Industrialization of Drug Discovery
- The Human Genome Project and the Rise of Omics
- Rise of the Personalized Medicine Paradigm
- Pharma in the Post-Genomic Era
- Omics for Drug Discovery
- Transcriptomics
- Positional DNA Microrrays
- Encoded Bead Arrays
- Proteomics
- Metabolomics
- Target Discovery
- Target Validation
- Omics for Drug Development
- Preclinical Development
- Clinical Development
- Omics and Systems Biology
CHAPTER 4: OMICS IN PHARMA R&D TODAY
- To What Extent Has Genomics Become Embedded in Pharma R&D?
- To What Extent Have Omic Technologies Proved Their Value?
- How Have Omic Technologies Fared in Target Identification?
- To What Extent Has SNP Genotyping Contributed to Target ID?
- What Are The Prospects for Omic-Based Toxicity Prediction?
- To What Extent Will Omics-Based Patient Stratification Be Practical?
- How Do Organizational Factors Play Into The Omics Equation?
CHAPTER 5: MARKET IMPLICATIONS OF R&D TRENDS
- Omic-Related Deals Involving Pharma
- Market for Omic Technology Products
- CHAPTER 6: COMPANY OMICS R&D SUMMARIES
- Abbott Laboratories
- AstraZeneca PLC
- Bristol-Myers Squibb
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline
- Merck & Co., Inc.
- Millennium Pharmaceuticals
- Novartis International AG
- Pfizer, Inc.
CHAPTER 7: INTERVIEWS WITH INDUSTRY EXPERTS
- Eugene Brown, Ph.D., Senior Director, Molecular Profiling and Biomarker Discovery, Biological Technologies, Wyeth Research Brian Edmonds, Ph.D., Group Leader for Enabling Technologies, Eli Lilly Stephen Naylor, Ph.D., Adjunct Professor of Genetics and Genomics, Boston University School of Medicine Dalia Cohen, Ph.D., Global Head of Functional Genomics, Novartis Institutes for Biomedical Research Anonymous Technology Manager in the Pharmaceuticals Division of a Large Organization with Diverse Product Lines Upper Level Manager in Big Pharma
REFERENCES
TABLE OF EXHIBITS
- Exhibit 3.1 The Affymetrix Microarray Assay Process
- Exhibit 3.2 The Affymetrix Photolithographic Array Production Process
- Exhibit 3.3 Quantum Dot Spectral Properties
- Exhibit 3.4 The Aclara eTagR Technology
- Exhibit 3.5 High Throughput Genomics Multiplexed Gene Expression Detection Technology
- Exhibit 3.6 Ciphergen ProteinChipR Technology
- Exhibit 3.7 Ciphergen Biomarker Discovery Technology
- Exhibit 3.8 A 2D Gel Illustrating a Typical Protein Electrophorogram
- Exhibit 3.9 Applications of Post-Genomic Biomarkers
- Exhibit 3.10 Selected Systems Biology Commercial Biomarker Offerings
- Exhibit 5.1 Selected Pharmaceutical Omic-Related Deals
- Exhibit 5.2 Current and Projected Revenues (2004 and 2009) for Omic Technology Products, By Technology Category
- Exhibit 5.3 Current and Projected Revenues (2004 and 2009) for Omic Technology Products, By Market Segment
